JP2025090679A5 - - Google Patents

Info

Publication number
JP2025090679A5
JP2025090679A5 JP2025036066A JP2025036066A JP2025090679A5 JP 2025090679 A5 JP2025090679 A5 JP 2025090679A5 JP 2025036066 A JP2025036066 A JP 2025036066A JP 2025036066 A JP2025036066 A JP 2025036066A JP 2025090679 A5 JP2025090679 A5 JP 2025090679A5
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
amino acid
antibody
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2025036066A
Other languages
English (en)
Japanese (ja)
Other versions
JP7904346B2 (ja
JP2025090679A (ja
Filing date
Publication date
Priority claimed from JP2021545713A external-priority patent/JP7709917B2/ja
Application filed filed Critical
Publication of JP2025090679A publication Critical patent/JP2025090679A/ja
Publication of JP2025090679A5 publication Critical patent/JP2025090679A5/ja
Priority to JP2026078137A priority Critical patent/JP2026119205A/ja
Application granted granted Critical
Publication of JP7904346B2 publication Critical patent/JP7904346B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2025036066A 2019-02-04 2025-03-07 コネキシン43抗体およびその使用 Active JP7904346B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026078137A JP2026119205A (ja) 2019-02-04 2026-05-07 コネキシン43抗体およびその使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962800869P 2019-02-04 2019-02-04
US62/800,869 2019-02-04
JP2021545713A JP7709917B2 (ja) 2019-02-04 2020-02-04 コネキシン43抗体およびその使用
PCT/US2020/016606 WO2020163353A1 (en) 2019-02-04 2020-02-04 Connexin 43 antibodies and use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021545713A Division JP7709917B2 (ja) 2019-02-04 2020-02-04 コネキシン43抗体およびその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026078137A Division JP2026119205A (ja) 2019-02-04 2026-05-07 コネキシン43抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2025090679A JP2025090679A (ja) 2025-06-17
JP2025090679A5 true JP2025090679A5 (cg-RX-API-DMAC7.html) 2025-08-21
JP7904346B2 JP7904346B2 (ja) 2026-08-12

Family

ID=71947290

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021545713A Active JP7709917B2 (ja) 2019-02-04 2020-02-04 コネキシン43抗体およびその使用
JP2025036066A Active JP7904346B2 (ja) 2019-02-04 2025-03-07 コネキシン43抗体およびその使用
JP2026078137A Pending JP2026119205A (ja) 2019-02-04 2026-05-07 コネキシン43抗体およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021545713A Active JP7709917B2 (ja) 2019-02-04 2020-02-04 コネキシン43抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026078137A Pending JP2026119205A (ja) 2019-02-04 2026-05-07 コネキシン43抗体およびその使用

Country Status (9)

Country Link
US (2) US12187794B2 (cg-RX-API-DMAC7.html)
EP (1) EP3920969A4 (cg-RX-API-DMAC7.html)
JP (3) JP7709917B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210153039A (cg-RX-API-DMAC7.html)
CN (2) CN112384244B (cg-RX-API-DMAC7.html)
AU (3) AU2020219112A1 (cg-RX-API-DMAC7.html)
CA (1) CA3128987A1 (cg-RX-API-DMAC7.html)
IL (2) IL320816A (cg-RX-API-DMAC7.html)
WO (1) WO2020163353A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116854816A (zh) 2018-04-02 2023-10-10 阿拉玛布治疗学股份有限公司 连接蛋白43抗体及其用途
IL300245A (en) * 2020-07-31 2023-03-01 Alamab Therapeutics Inc Anti-connexin antibody formulations
WO2025006774A1 (en) * 2023-06-30 2025-01-02 Alamab Therapeutics, Inc. Method of treating osteoarthritis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
AU2002362197A1 (en) * 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
US6745478B2 (en) 2002-07-18 2004-06-08 Delillo Dominick D. Multi-purpose work knife
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
CN101573131B (zh) * 2005-02-03 2017-12-01 科达治疗有限公司 抗‑连接蛋白化合物及其治疗应用
AU2009246640A1 (en) 2008-05-15 2009-11-19 Biogen Idec Ma Inc. Anti-Fn14 antibodies and uses thereof
WO2009148613A1 (en) * 2008-06-04 2009-12-10 Coda Therapeutics, Inc. Treatment of pain with gap junction modulation compounds
US8956868B2 (en) * 2010-12-27 2015-02-17 Lsip, Llc Induced pluripotent stem cells produced with a connexin inhibitor and a TGF-β signaling inhibitor
WO2015027120A1 (en) * 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
US9493552B2 (en) 2013-11-15 2016-11-15 China Synthetic Rubber Corporation Therapeutic biologic for treatment of hepatocellular carcinoma
WO2016029191A2 (en) * 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AU2017224122B2 (en) * 2016-02-26 2024-04-11 The Board Of Regents Of The University Of Texas System Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
CN116854816A (zh) 2018-04-02 2023-10-10 阿拉玛布治疗学股份有限公司 连接蛋白43抗体及其用途
IL300245A (en) * 2020-07-31 2023-03-01 Alamab Therapeutics Inc Anti-connexin antibody formulations

Similar Documents

Publication Publication Date Title
JP2025065427A5 (cg-RX-API-DMAC7.html)
JP2023538891A5 (cg-RX-API-DMAC7.html)
JP2024109678A5 (cg-RX-API-DMAC7.html)
CA2466629A1 (en) Expression control using variable intergenic sequences
JP2023093753A5 (cg-RX-API-DMAC7.html)
JP2025508827A5 (cg-RX-API-DMAC7.html)
JP2022191383A5 (cg-RX-API-DMAC7.html)
JP2023121798A5 (cg-RX-API-DMAC7.html)
JP2025109759A5 (cg-RX-API-DMAC7.html)
TW201815825A (zh) 經修飾之抗原結合fab片段及包含其之抗原結合分子
JP2023058590A5 (cg-RX-API-DMAC7.html)
CN115461368A (zh) 抗人白细胞介素-4受体α抗体及其制备方法和应用
JP2004041195A5 (cg-RX-API-DMAC7.html)
JP2020505017A5 (cg-RX-API-DMAC7.html)
JP2020505919A5 (cg-RX-API-DMAC7.html)
JP2007530435A5 (cg-RX-API-DMAC7.html)
JP2024056817A5 (cg-RX-API-DMAC7.html)
CN113354729A (zh) 一种抗新型冠状病毒的单克隆抗体及其应用
JP2022534135A5 (cg-RX-API-DMAC7.html)
JP2003527078A5 (cg-RX-API-DMAC7.html)
JP2004502409A5 (cg-RX-API-DMAC7.html)
JP2002503495A5 (cg-RX-API-DMAC7.html)
JP2020505927A5 (cg-RX-API-DMAC7.html)
JP2025067915A5 (cg-RX-API-DMAC7.html)
CN113785057A (zh) 用于抗体优化的变异核酸文库